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The amplification and/or overexpression of the c-erbB-2
(HER2/neu) oncogene product (p185c-erbB-2) is a frequent event in
different types of human cancer, including 20–30% of ovarian
cancers. In ovarian cancer the overexpression of p185c-erbB-2) char-
acterizes a subgroup of patients with unfavourable tumour biology
and poor prognosis (Berchuck et al, 1990; Meden et al, 1994). The
c-erbB-2 gene encodes a 185 000 wild-type receptor tyrosine
kinase with extensive homology to the epidermal growth factor
receptor and the c-erbB-3 and c-erbB-4 gene products (Yamamoto
et al, 1986; Kraus et al, 1989; Plowman et al, 1993). The members
of the erbB family are co-expressed in various combinations in
normal and neoplastic cells. Experimental evidence exists that the
binding of particular ligands to the other receptors of the erbB
family leads to the formation of heterodimers with p185c-erbB-2 and
that this tyrosine kinase receptor has an important function in
modulating signal transduction, called lateral signal transduction
(Graus-Porta et al, 1997).
It was previously demonstrated that the overexpression of the
human c-erbB-2 oncogene is able to transform mouse NIH 3T3
fibroblasts and that the transformed fibroblasts are able to form
tumours in mice (Hudziak et al, 1987). Furthermore in NIH 3T3
cells the point mutation-activated rat neu gene, the c-erbB-2
homologue, enhanced several metastasis/invasion-associated
properties like cell growth, DNA synthesis rate, increased
anchorage-independent growth rate and secretion of matrix-
degrading enzymes (Yu and Hung, 1991). However, the function
of the c-erbB-2 protooncogene and especially of the mutation-
activated neu oncogene in rodent mesenchymal cells cannot be
simply extrapolated to human ovarian cancer cells. The transition
of normal epithelial cells to invasive carcinoma is a complex and
multistage process involving enhanced proliferation, anchorage-
independent growth, ability to degrade basal membrane compo-
nents and cell migration. Therefore, systematic studies using
ovarian cancer cells are necessary to determine whether the
c-erbB-2 gene contributes to these parameters in ovarian cancer.
In this study, we investigated the role of the c-erbB-2 oncogene
product in human ovarian cancer cells by the intracellular reten-
tion of p185c-erbB-2 in c-erbB-2-overexpressing SK-OV-3 cells
using an intracellular single-chain antibody (Graus-Porta et al,
1995). In addition to anchorage-dependent and anchorage-
independent growth abilities we measured the secretion of matrix
metalloproteases (MMPs) and of the urokinase-type plasminogen
activator (uPA), which are key proteases implicated in extra-
cellular matrix proteolysis (Chambers et al, 1995; Tamakoshi,
et al, 1995). Our results demonstrate that the intracellular retention
of p185c-erbB-2 in SK-OV-3 ovarian cancer cells results in a loss of
transformation abilities. However, in SK-OV-3 ovarian cancer
cells the c-erbB-2 oncogene product is not involved in the secre-
tion of MMPs, uPA and in cell proliferation in the presence of high
concentrations of serum.
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Summary The overexpression of the c-erbB-2 oncogene product has been reported in approximately 20–30% of human ovarian cancers and
has been correlated with a poor prognosis in ovarian cancer patients. To investigate the function of p185c-erbB-2 in human ovarian cancer cells,
a c-erbB-2-specific single-chain antibody (scFv-5R) was expressed in the c-erbB-2-overexpressing SK-OV-3 cell line using a retroviral
expression vector. Eight individual clones expressing the single-chain antibody were isolated. These clones have a prominent retention of the
cell surface p185c-erbB-2. In this study we compared the proliferation rate, the anchorage-independent growth, the secretion of matrix
metalloproteases and of the urokinase-type plasminogen activator. The clones expressing the c-erbB-2 single-chain antibody, the control cells
harbouring the empty vector and the parental SK-OV-3 cells they all had similar proliferation rates in the presence of 10% serum and secreted
similar amounts of matrix metalloproteases and of the urokinase-type plasminogen activator. However, the expression of the c-erbB-2
oncogene product offers a strong growth advantage under serum-reduced conditions with 1% serum. In contrast to the parental SK-OV-3 and
empty vector control cells, the scFv-5R-expressing clones were not able to grow anchorage-independently. These findings suggest that c-
erbB-2 enhances transformation abilities of SK-OV-3 ovarian cancer cells without affecting the secretion of proteases and the proliferation of
SK-OV-3 ovarian cancer cells in the presence of high concentrations of serum. © 1999 Cancer Research Campaign
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MATERIALS AND METHODS
Materials and chemicals
The human ovarian cancer cell line SK-OV-3 was obtained from
the American Type Culture Collection (HTB #77). The c-erbB-2-
specific single-chain antibody scFv-5R vector pBP-5R was
gratiously provided by NE Hynes (Friedrisch Miescher Institut,
Basel, Switzerland). The scFv-5R coding sequence was excised
from pBP-5R with EcoRI and SalI, blunted with Klenow enzyme,
ligated with BamHI adaptors and cloned into the corresponding
site of the bicistronic retroviral expression vector pLIXN
(Clontech, Palo Alto, CA, USA), yielding pL5R. The proper
orientation of the scFv-5R insert was proved by restriction
analysis and by dideoxy sequencing. Phoenix-ampho retroviral
packaging cells were kindly supplied by GP Nolan (Stanford
University School of Medicine, CA, USA).
Cell culture
Stock cultures of SK-OV-3 and Phoenix-ampho cells were main-
tained at 37°C in a humidified atmosphere of 5% carbon dioxide
and 95% air in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal calf serum (FCS) and 2-mM glutamine.
Expression of the c-erbB-2-directed scFv-5R in
SK-OV-3 cells
A total of 2 ´ 106 Phoenix-ampho packaging cells were plated on
60-mm cell culture dishes. After 24 h, 4 mg of Quiagen-purified
pL5R or pLIXN plasmid DNA were transfected as previously
described (Pear et al, 1993). Two days after transfection, the 
virus-containing supernatant was harvested and used immediately
for infection or stored frozen at –80°C. For the infection 2 ´ 105
SK-OV-3 cells were plated on 60-mm cell culture dishes. After
24 h infection was performed with the scFv-virus or neo control
virus-containing medium in the presence of 8 mg ml–1 polybrene
(Sigma, St Louis, MO, USA). After 2 days the infected SK-OV-3
cells were subjected to selection in 1.5 mg ml–1 geneticin (G418,
Calbiochem, San Diego, CA, USA). Two weeks later individual
G418-resistant clones were isolated and maintained with
0.75 mg ml–1 G418. Pools of neo-transfected cells were used as
a control.
RNA isolation and Northern blot analysis
Total RNA was extracted by the acid guanidinium thiocyanate
extraction method. Ten micrograms of total RNA per lane was
size-fractionated on 0.8% agarose, 2.2% formaldehyde gels and
blotted to nylon membranes by capillary transfer. The blots were
hybridized with the EcoRI–SalI scFv-5R cDNA fragment from
pBP-5R and labelled with 32P-dCTP to a specific activity of
2 ´ 108 to 6 ´ 108 cpm per mg of DNA. After hybridization the
blots were washed under high stringency conditions and exposed
for 24 h at –80°C to Amersham MP film using intensifying
screens. Equivalent loading of RNA was confirmed by ethidium
bromide staining of the 28S and 18S rRNAs and by hybridizing
with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA probe.
Flow cytometry
A total of 2 ´ 105 SK-OV-3 cells were seeded on 60-mm culture
dishes and after 24 h detached with 2 mM ethylenediamine
tetraacetic acid (EDTA) in phosphate-buffered saline (PBS). The
cells were then incubated with the p185c-erbB-2-specific monoclonal
antibody TA-1 (Oncogene Science) at 0.2 mg ml–1. Cells were
incubated on ice for 1 h and subsequently incubated for 45 min
with a R-phycoerythrin (PE)-labelled goat anti-mouse conjugate
(Sigma, St Louis, MO, USA). The cells were then analysed with a
Becton-Dickinson flow cytometer using the 488 nm excitation line
of the argon laser. PE fluorescence was collected through a 585 nm
band pass filter. Mouse IgG with irrelevant specificity was used as
a control.
Monolayer cell growth
The growth rates of SK-OV-3 cells and their derivatives were
assessed by measuring relative increases in cell number using an
XTT assay (Boehringer Mannheim, Germany). One thousand cells
were plated in 96-well flat-bottom culture wells in 0.1 ml of
culture medium supplemented with 10% or 1% FCS. From day 1
to day 6 XTT reagent was added to one row (8 wells) of the plate
as recommended by the manufacturer. Formazan dye was
measured in a microplate reader after 4 h at 470 nm. The 
proliferation experiments were performed a least three times
independently.
Anchorage-independent cell growth
Anchorage-independent cell growth was measured in micro-
titre plates coated with poly(2-hydroxyethyl methacrylate)
(poly(HEMA)) as described previously (Fukazawa et al, 1995).
Briefly, 50 ml of poly(HEMA) (Sigma), dissolved at 5 mg ml–1 in
95% ethanol was applied into wells of 96-well plates. The plates
were allowed to dry for 2 days at 37°C. Cells were seeded in a
volume of 150 ml into each well at a density of 1000 cells per well.
On the following days 1–6 50 ml of XTT reagent (Boehringer
Mannheim, Germany) was added and further incubated for 4 h.
The absorbance was measured at 470 nm.
Measurement of proteases
Secreted proteases were measured in serum-free conditioned cell
culture medium. Then, 2 ´ 105 cells were seeded on 12-well tissue
culture plates in DMEM supplemented with 10% FCS and
cultured overnight. The cells were washed two times with 
serum-free DMEM with 0.1% bovine serum albumin (BSA) and
incubated with 250 ml DMEM/0.1% BSA for 16 h. Matrix
metalloproteases were determined using a zymographic assay.
Briefly, the culture supernatant was subjected to 10% sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
with 1.5% gelatin incorporated in the separating gel under non-
reducing conditions. The gel was then washed with 2.5% Triton
X-100 in 50 mM Tris–HCl, pH 7.5 and incubated for 16 h in
0.15 M sodium chloride, 10 mM calcium chloride in 50 mM
Tris–HCl, pH 7.5. Afterwards the gel was stained with Coomassie
brilliant blue and destained. uPA concentrations were determined
by using a commercially available enzyme-linked immunosorbent
assay (ELISA) kit (American Diagnostica, Greenwich, CT, USA)
as recommended by the manufacturer.792 K Wiechen et al
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RESULTS
We expressed the c-erbB-2-specific single-chain antibody scFv-5R
of Hynes and collaborators (Graus-Porta et al, 1995) in the
c-erbB-2-overexpressing SK-OV-3 ovarian cancer cell line. This
single-chain antibody has been shown to interfere with the func-
tion of p185c-erbB-2 in human cancer cells of different histologic
origin (Beerli et al, 1995). Eight stable individual clones were
isolated that express high levels of the scFv-5R RNA as revealed
by Northern blot hybridization (Figure 1). These clones have an
almost complete retention of the cell surface p185c-erbB-2 level as
measured by flow cytometric analysis (Figure 2). The clones were
morphologically similar to the parental SK-OV-3 cell line and to
the control cells carrying the empty vector with the neo selectable
marker (not shown).
The influence of cell surface p185c-erbB-2 on cell proliferation was
measured by comparing relative increases in cell number with a
colourimetric XTT assay. In these experiments the growth rates of
the parental SK-OV-3 cells, the neo control cells expressing the
empty vector and the individual clones expressing scFv-5R did
not show significant differences in the presence of 10% FCS
(Figure 3A). However, the anchorage-dependent cell proliferation
of the individual clones expressing scFv-5R was strongly inhibited
in the presence of 1% FCS (Figure 3B).
We then compared the growth rates of the cells in microtitre
plates coated with poly(HEMA). Under these conditions the cells
were not able to adhere to the bottom of the wells and to spread.
The parental SK-OV-3 cells and the neo control cells show rapid
growth under anchorage-independent conditions and formed
three-dimensional colonies in the coated wells. In contrast, the cell
clones expressing scFv-5R were not able at all to grow under
anchorage-independent conditions (Figure 3C). We have in addi-
tion performed experiments where the cells were immersed in soft
agar with comparable results (not shown).
Secretion of MMPs was measured using a zymographic assay
(Figure 4A). In conditioned cell culture medium of SK-OV-3 cells
the 72 kDa MMP-2 (gelatinase A, MMP-2) is easily detectable.
The 92 kDa MMP (gelatinase B, MMP-9) is not detectable in the
conditioned medium. No significant alterations in MMP-2 levels
are seen in the clones expressing scFv-5R or the control cells as
compared to the parental SK-OV-3 cells.
In addition, we have measured the amounts of uPA in the condi-
tioned medium of SK-OV-3 cells and their derivatives using an
123456
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Figure 1 (Upper panel) Expression of scFv-5R RNA. Ten micrograms of
total RNA per lane was electrophoresed, blotted and probed with a scFv-5R-
specific 32P-labelled probe. Lane 1, SK-OV-3, lane 2, neo control cells, lanes
3–6, representative individual cell clones expressing scFv-5R. (Lower panel)
Hybridization with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA probe to confirm equal loading amounts
Figure 2 Detection of p185c-erbB-2 by a flow cytometric assay. The cells were
detached with EDTA/PBS and subsequently incubated with a c-erbB-2-
specific monoclonal antibody and then with a R-phycoerythrin (PE)-labelled
secondary antibody. Loss of cell surface p185c-erbB-2 in cell clones expressing
the scFv-5R. Data shown are from 2 representative individual cell clones
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ELISA assay. As shown in Figure 4B similar concentrations of
uPA are present in the conditioned medium of SK-OV-3 cells, the
neo control cells and the clones. The small differences of the uPA
concentrations between the individual cell clones may represent a
clonal variation. This is reflected by the very similar uPA values
when comparing the data of the controls (SK-OV-3 and neo) with
the sum data from the individual clones (Figure 4B, bar on the
right)
DISCUSSION
Clinical data suggest an important function of p185c-erbB-2 in
malignant epithelial tumours of different histologic origin
including ovarian cancer. Although c-erbB-2 overexpression was
previously shown to be correlated with a poor prognosis
(Berchuck et al, 1990; Meden et al, 1994) the precise functions of
p185c-erbB-2 in ovarian cancer are not very well understood. The
majority of data about the function of c-erbB-2 was derived from
experiments using overexpression of the c-erbB-2 gene in rodent
mesenchymal cells. To investigate the role of p185c-erbB-2 in human
ovarian cancer cells, we have used the c-erbB-2-specific intra-
cellular single-chain antibody of Hynes and collaborators (Graus-
Porta et al, 1995) to suppress the c-erbB-2 gene product in the
overexpressing SK-OV-3 cell line. This single-chain antibody
causes specific intracellular retention of the c-erbB-2 gene
product. It does not interfere with the synthesis or stability of
p185c-erbB-2. However, in tumour cells expressing scFv-5R the
c-erbB-2 gene product shows a faster electrophoretic mobility
which may be due to hypoglycosylation by intracellular retention
(Graus-Porta et al, 1995). It was, in addition, previously shown
that the expression of the EGF receptor and the c-erbB-3 gene
product are not influenced by the scFv-5R single-chain antibody
(Graus-Porta et al, 1995).
Individual cell clones with a complete retention of the cell
surface p185c-erbB-2 lost the ability of the parental SK-OV-3 tumour
cells to grow anchorage-independently. The ability of the c-erbB-2
oncogene to transform cells and to induce anchorage-independent
growth abilities was first described in NIH 3T3 mouse fibroblasts
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Figure 3 (A and B) Similar growth rates among the scFv-5R-expressing
clones and the control cells in the presence of 10% FCS (A) and growth
inhibition of the scFv-expressing clones in the presence of 1% FCS (B). Cells
(1 ´ 103) were plated on microtitre plates. Relative increases in cell number
were measured using an XTT test on different days for 6 days. The OD 470
is given as mean ± s.e.m. (C) Loss of anchorage-independent growth abilities
of cell clones expressing scFv-5R. One thousand cells were plated on
poly(HEMA) coated microtitre plates. Relative increases in cell number were
measured using a XTT test on different days for 6 days. The OD 470 is given
as mean ± s.e.m. Data shown are from parental SK-OV-3 cells, neo control
cells and two representative cell clones expressing scFv-5R794 K Wiechen et al
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(Hudziak et al, 1987). However, in SV40-immortalized human
bronchial epithelial cells the overexpression of c-erbB-2 was not
sufficient to enhance anchorage-independent growth abilities and
only one cell clone was able to form tumours in vivo (Noguchi
et al., 1993). Other experiments using tumour cell lines also show
different results when analysing the c-erbB-2 function in cell
transformation. The enhanced expression of c-erbB-2 in SK-OV-3
cells after an animal passage resulted in enhanced anchorage-
independent growth abilities (Yu et al, 1993). In contrast, in human
MDA-MB-435 breast cancer cells that express only low amounts
of endogenous p185c-erbB-2 the overexpression of c-erbB-2 does not
result in enhanced anchorage-independent growth abilities (Tan
et al, 1997).
The intracellular retention of p185c-erbB-2 does not influence the
anchorage-dependent proliferation of SK-OV-3 ovarian cancer
cells in the presence of high concentrations of serum. Recently it
was shown that transfection of a human c-erbB-2 vector into
hormone-dependent MCF-7 human breast cancer cells is able to
inhibit cell growth and to induce cell differentiation (Giani et al,
1998). Although we have not analysed the sensitivity of SK-OV-3
to steroid hormones, the growth of the SK-OV-3 derivatives in the
presence of 10% serum was independent from the cell surface
p185c-erbB-2.
However, the expression of the c-erbB-2 gene product offers
a strong growth advantage under serum-reduced conditions.
Therefore cell transformation consisting of enhanced growth abili-
ties under serum-reduced or anchorage-independent conditions
and cell proliferation in the presence of high concentrations of
serum of SK-OV-3 ovarian cancer cells may be mediated by
different non-overlapping signal transduction pathways.
Previously, Deshane and colleagues have used another single-
chain antibody to suppress c-erbB-2 in cancer cells. This
single-chain antibody was expressed transiently using the adeno-
virus-polylysine technique and a recombinant adenovirus
(Deshane et al, 1995a, 1995b, 1996). They reported specific induc-
tion of apoptosis in SK-OV-3 and other c-erbB-2-overexpressing
human cancer cell lines. The increased rate of apoptosis in these
experiments resulted in a decrease of anchorage-dependent
(Deshane et al, 1996) and anchorage-independent growth abilities
(Deshane et al, 1995a). In addition the expression of this single-
chain antibody using adenovirus transfer was able to inhibit
tumour growth in vivo (Deshane et al, 1995b). In our experiments,
the single-chain antibody scFv-5R was expressed stably for a long-
term using a retroviral vector. Increased amounts of dead cells that
may be attributed to apoptosis were not observed in our experi-
ments with SK-OV-3 cells under anchorage-dependent conditions.
The induction of apoptosis in SK-OV-3 cells under anchorage-
dependent conditions observed by Deshane and colleagues may be
due to the very high level of transient expression by the adenovirus
vector and/or be directly caused by the different single-chain anti-
body targeted against the c-erbB-2 gene product.
In addition to cell proliferation and transformation, invasive
and metastatic tumour growth involves the degradation of basal
membrane components and of the surrounding stroma by
proteases. Therefore we measured the secreted amounts of MMPs
and uPA. The secretion of MMPs is independent of p185c-erbB-2 in
SK-OV-3 ovarian cancer cells. In contrast, in human MDA-MB-
435 breast cancer cells, the overexpression of the c-erbB-2 onco-
gene enhances the intrinsic metastatic potential by increasing
secreted activities of MMPs (Tan et al, 1997).
Another key protease implicated in invasive tumour growth,
uPA, was previously shown to be significantly elevated in
peritoneal metastases of ovarian carcinomas as compared to
primary tumours (Schmalfeldt et al, 1995). In SK-OV-3 ovarian
cancer cells the secreted amounts of uPA are independent of
p185c-erbB-2. In contrast in mouse NIH 3T3 fibroblasts and in human
H460 lung cancer cells uPA is up-regulated by the expression of
p185c-erbB-2 (Gum et al, 1995). On the basis of our experiments
we cannot exclude that other types of proteases are regulated
p185c-erbB-2-dependently in SK-OV-3 cells.
To sum up, parameters involved in tumour progression are
regulated by the c-erbB-2 gene product in a cell type-specific
fashion. Our results show that the c-erbB-2 gene product regulates
the transformation abilities in SK-OV-3 ovarian cancer cells. In
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Figure 4 (A) Secretion of similar amounts of matrix metalloproteases by
SK-OV-3 cells (lane 1), neo control cells (lane 2) and 4 representative scFv-
5R-expressing cell clones (lanes 3–6). A total of 2 ´ 105 cells were seeded on
12-well tissue culture plates. The cells were incubated with DMEM/0.1% BSA
for 16 h. Cultured media were subjected to SDS-PAGE (gel containing 1.5%
gelatin) without reducing agent. The gel was afterwards incubated in reaction
buffer and stained with Coomassie Brilliant Blue, and destained. The position
of the 72-kDa matrix metalloprotease (MMP-2) is indicated. (B) Secretion of
similar amounts of uPA by SK-OV-3 cells, neo control cells and 4
representative scFv-5R-expressing cell clones. The conditioned medium was
prepared as described above. The uPA concentration was measured using a
commercially available ELISA assay. Left-hand bars, uPA concentration of
SK-OV-3, neo controls and 4 representative individual scFv-expressing cell
clones (Y-axis in ng ml–1 ± s.e.m.). Right-hand bar, sums of uPA
concentrations of the 4 scFv-5R-expressing cell clones
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addition we have previously shown that SK-OV-3 cells express
EGF receptors together with p185c-erbB-2 and that p185c-erbB-2 is
involved in EGF-induced tumour cell motility in SK-OV-3 cells
(Weichen et al, submitted). Therefore it is likely that in SK-OV-3
cells p185c-erbB-2 modulates signal transduction pathways to the
cytoskeleton and the actomyosin system and/or transcriptionally
regulates involved genes.
Ovarian cancer is the most lethal tumour of the female genital tract
and continues to be the major cause of female cancer mortality,
largely as a function of early abdominal seeding producing peritoneal
carcinosis and ascites. In contrast to other human epithelial malig-
nancies, the generation of distant metastases is uncommon in ovarian
cancer. This may be reflected by the p185c-erbB-2 independence of the
secretion of matrix-degrading enzymes in the SK-OV-3 cell system.
This point of view is supported by the fact that MMP levels are
significantly higher in cervical and endometrial cancer that are
characterized by metastatic progression compared to ovarian cancer
(Tamakoshi et al, 1995). The reorganization of the cytoskeleton by
the overexpression of p185c-erbB-2 involved in enhanced anchorage-
independent growth may contribute to the formation of malignant
ascites and to the peritoneal spread of tumour cells characteristic for
ovarian cancer and thus contribute to the poor prognosis of
c-erbB-2-overexpressing tumours.
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